Bio-Techne rebrands genome engineering as part of R&D Systems portfolio

By The Science Advisory Board staff writers

September 21, 2020 -- Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

The company's B-MoGen Biotechnologies portfolio of genome engineering services, good manufacturing practice therapeutic manufacturing services, and proprietary transposon-transposase gene transfer system, TcBuster, has been rebranded under R&D Systems.

As part of the rebranding, the B-MoGen Biotechnologies website will be retired. All service details and purchasing options will be maintained on the R&D Systems website. The consolidation will help the company provide customers with discovery-to-clinic cell and gene therapy solutions.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?